Galena Breast Cancer Vaccine Receives Patent Exclusivity

Big news for breast cancer survivors–The Sun Sentinel reports that the Galena Biopharma breast cancer vaccine has received a patent granting it exclusivity until 2028.

The vaccine, NeuVax, gives immunity against the relapse of breast cancer in patients who have low-to-intermediate levels of HER2, which is a protein that can affect the growth of cancer cells.

Currently being test in a late stage study, NeuVax has a special protocol assessment agreement with the FDA.

Once approved, NeuVax will be administered as an injection once a month for six months, followed by a booster injection once every six months.

More than 230,000 women in the U.S. alone are diagnosed with breast cancer every year.